Michael Skynner, Ph.D.Chief Operating Officer at Bicycle Therapeutics
Michael Skynner, Ph.D., is chief operating officer at Bicycle Therapeutics responsible for global operations, the platform, discovery and strategic alliances. He has over 22 years of pharm/biotech experience and joined Bicycle in 2016 from Pfizer, where he led rare disease efforts in Europe and founded both the Pfizer Rare Disease Consortium & Genetic Medicine Institute. Previously, he established a discovery performance unit at GSK focused on developing clinical small-molecule therapeutics targeting inflammatory kinases. Prior to GSK he co-founded a successful peptide-based biotech start-up company, Cambridge Biotechnology Ltd., which was sold to Swedish Orphan Biovitrum.